News

Our Hong Kong Foundation (OHKF) has released its latest Land and Housing Policy Research report, titled "Immediate Actions to Resolve Hong Kong's Housing Conundrum: Cut the Red Tape Now!
 
 
On 24 January 2022.  (OHKF) call on the HKSAR Government to resolve Hong Kong's housing supply shortage immediately by addressing the pain points at three levels: cumbersome development procedures, inefficient policy implementation, and conflicting social opinions.  The report puts forward 23 detailed recommendations with the goals of expediting housing supply in the short run and reducing public housing waiting time.
 

 

 https://ourhkfoundation.org.hk/sites/default/files/media/pdf/Eng_Land&Housing_Report_2022.pdf

 

26/01/2022

生物科技專家常海解讀,香港遭雙毒株衝擊民眾如何安度春節?

最近Omicron來勢洶洶,在世界很多國家幾何式爆發,香港好不容易守住的80多天本地零感染也被突破,以防蔓延,嚴謹的防疫措施正在進行中。較早前鳳凰網香港號陳笺邀請生物科技專家于常海網上的訪問,解讀  "香港遭雙毒株衝擊",也解析 "為何世衛建議放開旅遊限制",來探討幾個相關核心提要。(鳳凰網香港號主持人:陳笺)

 

29/07/2021

Prof. Cheng Hon-ki Christopher, Professor at the School of Biomedical Sciences of The Chinese University of Hong Kong (CUHK), former Deputy Vice-President of Hong Kong Biotechnology Organization (HKBIO), passed away because of illness, peacefully, at home on July 12.

His memorial ceremony will be held at the Po Fook Hall on the ground floor of the Po Fook Memorial Hall in Tai Wai at 5 pm on August 7, 2021 (Saturday). The funeral ceremony will start at 11 am on August 8, 2021 (Sunday), and the body will be sent for cremation at 12 o’clock. There will be no special religious ceremony.

Obituary notice.

09/06/2021

市民打了疫苗後,若接受抗體檢測結果呈陽性,代表接種了兩針疫苗,或者曾受病毒染疫。不過,個別人士打針或染疫後,身體是不會產生抗體的。香港檢測和認證局主席于常海教授表示,其實驗室約三十名打了針職員,早前檢驗自身的抗體水平,發現年輕員工的抗體水平不錯,但一名長期服藥員工的抗體水平相當低,接近「無抗體」。他指,業界正研究市民打針後,一旦感染病毒,記憶B細胞能否辨識並作出反應。于教授強調,「打針一定有用過唔打」,只有極少數人不產生抗體。

呼吸系統專科醫生梁子超亦稱,現階段不能以抗體水平來決定保護性,細胞免疫也與保護有關,而人體打針後會否出現抗體,因人而異,視乎個人身體情況及暴露於病毒的程度及時長。除了特殊醫療需要,一般市民是不需檢驗抗體水平。

30/05/2021

粵港澳大灣區生物科技聯盟昨日舉辦論壇,探討大灣區的發展及機遇。食物及衞生局前局長高永文表示,期望大灣區逐步放寬「港醫港藥」北上,讓港資醫療機構可在內地落地。創新及科技局局長薛永恒昨在電台節目亦指,大灣區青年就業計畫相當受歡迎,已增加與創科有關的職位,未來可能擴展計畫到其他城市。 

早前「港澳藥械通」以試點形式,率先在香港大學深圳醫院展開。食衞局前局長、全國政協委員高永文昨日表示,近年不少港資醫療集團正逐步開拓大灣區市場,但由於內地法規要求所有藥物均須在內地作臨牀研究,並在審批後才獲准使用,因此港資醫療機構只能使用同款或仿製藥物。他期望,計畫可擴展至其他港資醫院。

Free Joomla! template by Age Themes